Novo Nordisk’s Wegovy and copyright, both of those powered by semaglutide, have revolutionized obesity treatment by means of unparalleled weight loss success. In October 2024, Novo Nordisk revealed a analyze on scientific journal Mother nature a few novel glucose-delicate insulin NNC221